Friday, Apr 19 2024 | Time 16:32 Hrs(IST)
image
Business Economy


Lupin and Mylan receive European marketing authorization for Nepexto

Mumbai , Jun 4 (UNI) Lupin Limited and Mylan NV on Thursday announced that the European Commission (EC) has granted marketing authorisation for Nepexto, a biosimilar to Enbrel (etanercept).
The EC has granted marketing authorisation for Nepexto for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
The regulatory approval follows the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) in March this year, which was based on a biosimilarity assessment including preclinical and clinical studies demonstrating bioequivalence to Enbrel.
In addition, a phase 3 clinical study in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to Enbrel in terms of efficacy, safety and immunogenicity, Lupin said in a filing with BSE.
The centralised marketing authorisation applies to all member countries of the European Union.
Vinita Gupta, CEO, Lupin Limited said, "We are truly delighted with this approval. Nepexto is our first biosimilar to receive regulatory approval in Europe. With this important milestone, we bring an affordable biosimilar to the European market through our partner Mylan. Biosimilars like Nepexto will play a critical role in expanding access to patients in Europe, providing an effective treatment for multiple therapies including rheumatoid arthritis."
Mylan President, Rajiv Malik commented, "The approval of Nepexto, our biosimilar etanercept, is a positive step forward as we work to broaden our biosimilars franchise offerings and do our part to increase access to biologic treatments for patients in many European countries. This milestone reflects a strong scientific program behind Nepexto and commitment by our teams and our partner, Lupin, to bring the product to market as soon as possible. We look forward to launching Nepexto in the second half of this year."
Enbrel had sales of approximately 9.6 billion dollars globally for the 12 months ending December 2019, according to IQVIA.
UNI JS NV SV 1824
More News
India International Industrial Expo in Kochi from Dec 13-15, 2024

India International Industrial Expo in Kochi from Dec 13-15, 2024

19 Apr 2024 | 12:56 PM

Kochi, Apr 19 (UNI) India International Industrial Expo (IIIE-2024), a gateway to a comprehensive industrial showcase, will be held here on December 13, 14 and 15, 2024 with the participation of more than 10,000 trade visitors and 350 leading Industrial manufacturers, IIIE CEO Siji Nair said on Friday.

see more..
NTPC green energy inks MoU with Indus Towers

NTPC green energy inks MoU with Indus Towers

19 Apr 2024 | 12:05 PM

Mumbai, Apr 19 (UNI) NTPC Green Energy Limited (NGEL) and Indus Towers Limited (ITL) on Friday signed a Memorandum of Understanding (MoU) to address the need for pacing green energy objectives and the GoI’s efforts towards a carbon-neutral economy.

see more..
Rupee opens record low at 83 55 against USD

Rupee opens record low at 83 55 against USD

19 Apr 2024 | 11:50 AM

Mumbai, Apr 19 (UNI) The rupee on Friday opened at a record low of 83.55, declining three paise amid geographical tension between Israel and Iran and rising demand for the US dollar by bankers and importers, dealers at the Foreign Exchange said.

see more..
Sensex drops over 500 points

Sensex drops over 500 points

19 Apr 2024 | 11:31 AM

Mumbai, Apr 19 (UNI) The equity market continued to fall for the fifth consecutive session on Friday as BSE Sensex crashed 539 points to open below 72K at 71,949.65 amid heightened geographical tension, triggering a massive selloff of global equities.

see more..

USD up ; Euro,Pound down

19 Apr 2024 | 10:08 AM

Mumbai, Apr 19 (UNI) Following were the indicative currency rates and travellers' cheques
buying and selling rates.

see more..
image